Key statistics
On Thursday, Organon & Co (OGN:NYQ) closed at 14.96, 7.86% above its 52-week low of 13.87, set on Dec 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.03 |
---|---|
High | 15.46 |
Low | 14.86 |
Bid | 14.85 |
Offer | 15.50 |
Previous close | 15.00 |
Average volume | 3.79m |
---|---|
Shares outstanding | 257.54m |
Free float | 257.08m |
P/E (TTM) | 2.90 |
Market cap | 3.77bn USD |
EPS (TTM) | 5.04 USD |
Annual div (ADY) | 1.12 USD |
---|---|
Annual div yield (ADY) | 7.47% |
Div ex-date | Feb 24 2025 |
Div pay-date | Mar 13 2025 |
Data delayed at least 15 minutes, as of Mar 13 2025 20:00 BST.
More ▼
- New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older
- Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024
- Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025
- Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference
- FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
More ▼